Photocure ASA ( (PHCUF) ) just unveiled an announcement.
Photocure ASA reported a strong first quarter in 2025 with revenues of NOK 125.3 million and an EBITDA of NOK 1.8 million, driven by robust performance in Europe and ongoing business development in North America. The company anticipates a 7% to 11% growth in product revenue and improved EBITDA for the year, supported by new installations and upgrades of blue light cystoscopy equipment. Photocure continues to expand its market presence with strategic collaborations and expects its innovative technology to become the standard of care in bladder cancer treatment.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, specializes in transformative solutions for bladder cancer treatment. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange. Photocure’s unique technology enhances cancer cell detection by making them glow bright pink, improving patient outcomes globally.
Average Trading Volume: 74,063
Current Market Cap: NOK1.42B
See more insights into PHCUF stock on TipRanks’ Stock Analysis page.